Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUTOPROL vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of metoprolol tartrate (beta-1-selective adrenergic receptor blocker) and hydrochlorothiazide (thiazide diuretic inhibiting Na+/Cl- cotransporter in distal convoluted tubule).
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Hypertension,Off-label: heart failure (metoprolol component), edema
Hypertension
1 tablet (containing 12.5 mg hydrochlorothiazide and 50 mg losartan) orally once daily; may increase to 1 tablet (12.5 mg/100 mg) once daily if inadequate response.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Bisoprolol: 10-12 hours, allowing once-daily dosing; Hydrochlorothiazide: 6-15 hours, prolonged in renal impairment.
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Metoprolol: primarily CYP2D6; Hydrochlorothiazide: not metabolized, excreted unchanged in urine.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Renal: 40-50% as unchanged drug and metabolites (hydrochlorothiazide and bisoprolol); Fecal/Biliary: <15%.
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
Bisoprolol: 30% bound to albumin; Hydrochlorothiazide: 40-68% bound to plasma proteins (predominantly albumin).
Approximately 70-80% bound to plasma proteins, primarily albumin.
Bisoprolol: 3.5 L/kg, reflecting extensive tissue distribution; Hydrochlorothiazide: 0.83 L/kg, indicating distribution in extracellular fluid.
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Oral: Bisoprolol 90% (high, first-pass negligible); Hydrochlorothiazide 65-75%.
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
Contraindicated if GFR <30 m L/min/1.73 m². For GFR 30-60 m L/min/1.73 m²: no dose adjustment required, but monitor potassium and creatinine. For GFR <30 m L/min/1.73 m²: do not use.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Child-Pugh Class A or B: no dose adjustment; use with caution. Child-Pugh Class C: not recommended.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Not approved for use in pediatric patients (safety and efficacy not established).
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Start at lowest possible dose; monitor renal function and electrolytes. No specific dose adjustment required if renal function normal, but elderly more susceptible to hypotension and electrolyte imbalance.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
None.
None.
Exacerbation of ischemic heart disease upon abrupt withdrawal of beta-blocker.,Bronchospasm in patients with bronchospastic disease.,May mask signs of hyperthyroidism or hypoglycemia.,Electrolyte disturbances (hypokalemia, hyponatremia) due to thiazide.,May increase serum uric acid and precipitate gout.,May cause photosensitivity reaction.
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Sinus bradycardia, heart block greater than first degree, cardiogenic shock, overt cardiac failure.,Bronchial asthma or significant COPD.,Anuria or hypersensitivity to sulfonamide-derived drugs (thiazides).
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
DUTOPROL should be taken 30 minutes after the same meal each day to reduce variability in absorption. Grapefruit juice inhibits CYP3A4 and can increase dutasteride levels; avoid concomitant consumption. High-fat meals may alter absorption, but consistent timing with a meal minimizes fluctuations. No other specific food interactions are known, but maintain a balanced diet and avoid excessive alcohol, which can worsen dizziness or hypotension.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
Category D: First trimester exposure associated with fetal bradycardia, intrauterine growth restriction, and oligohydramnios; second and third trimester use may cause fetal hypotension, hypoglycemia, and decreased placental perfusion.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Excreted in breast milk; M/P ratio not established. Use with caution, monitor infant for bradycardia and hypotension.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
Dose may need reduction due to increased plasma volume and clearance; individualize based on maternal blood pressure and fetal status.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
DUTOPROL is a fixed-dose combination of dutasteride (0.5 mg) and tamsulosin (0.4 mg) used for benign prostatic hyperplasia (BPH). Due to dutasteride's long half-life (~5 weeks), clinical effect on prostate volume may take 3–6 months. Tamsulosin, an alpha-1 blocker, can cause orthostatic hypotension, especially when initiated; titrate cautiously in elderly or those on antihypertensives. Avoid concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) as they increase dutasteride exposure. Measure PSA before starting and periodically thereafter; dutasteride halves PSA levels after 6 months, so adjust interpretation. Do not use in women or children.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take this medication exactly as prescribed, usually once daily, 30 minutes after the same meal each day to maintain consistent absorption.,Do not crush, chew, or open the capsules; swallow them whole to avoid irritation.,This drug can cause dizziness, lightheadedness, or fainting, especially when first starting or if you take blood pressure medications. Get up slowly from sitting or lying down.,Avoid grapefruit juice and grapefruit products as they may affect how the drug works.,Inform your doctor if you experience any of the following: severe dizziness, difficulty urinating, chest pain, or signs of an allergic reaction (rash, itching, swelling).,Do not donate blood while taking this medication and for at least 6 months after stopping, as the drug can be present in blood and cause harm to a pregnant woman or her baby.,If you are having cataract surgery, tell your surgeon you are taking this drug, as it may increase the risk of intraoperative floppy iris syndrome (IFIS).,This medication may cause a decrease in sexual desire, difficulty with erections, or reduced semen volume. These side effects are generally reversible after stopping treatment.,Women who are pregnant or could become pregnant should avoid handling crushed or broken capsules due to risk of harm to the unborn baby.,Regular follow-ups with your healthcare provider for PSA testing and symptom monitoring are important to assess treatment response and adjust dose if needed.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUTOPROL vs ALDOCLOR-150, answered by our medical review team.
DUTOPROL is a Antihypertensive Combination that works by Combination of metoprolol tartrate (beta-1-selective adrenergic receptor blocker) and hydrochlorothiazide (thiazide diuretic inhibiting Na+/Cl- cotransporter in distal convoluted tubule).. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUTOPROL and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUTOPROL is: 1 tablet (containing 12.5 mg hydrochlorothiazide and 50 mg losartan) orally once daily; may increase to 1 tablet (12.5 mg/100 mg) once daily if inadequate response.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUTOPROL and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUTOPROL is classified as Category C. Category D: First trimester exposure associated with fetal bradycardia, intrauterine growth restriction, and oligohydramnios; second and third trimester use may cause fetal hypoten. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.